公开(公告)号：US20130122019A1

公开(公告)日：2013-05-16

申请号：US13742680

申请日：2013-01-16

Applicant: GENE TECHNO SCIENCE CO., LTD.

Inventor： Shigeyuki Kon ,  Toshimitsu Uede

IPC: C07K16/28

CPC classification number: C07K16/2839 ,  C07K2317/76 ,  G01N2333/70546

Abstract: The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.

Abstract translation: 本发明涉及抗人α9整联蛋白抗体。 更具体地，本发明涉及：特异性识别人α9整联蛋白的单克隆抗体，嵌合抗体，人源化抗体和人抗体; 产生单克隆抗体的杂交瘤细胞; 生产单克隆抗体的方法; 用于产生杂交瘤细胞的方法; 包含抗人α9整联蛋白抗体的治疗剂; 包含人α9整联蛋白抗体的诊断剂; 以及筛选抑制人α9整联蛋白活性的化合物的方法。

公开(公告)号：US20130084285A1

公开(公告)日：2013-04-04

申请号：US13593285

申请日：2012-08-23

Applicant: Harald Mottl

Inventor： Harald Mottl

IPC: C07K16/28

CPC classification number: C07K16/2839 ,  A61K2039/505 ,  C07K16/2842 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: The invention relates to a formulation of an anti-α2 integrin antibody for administration to a patient, which is suitable for the treatment of cancer.

Abstract translation: 本发明涉及用于给予患者的抗α2整联蛋白抗体的制剂，其适用于治疗癌症。

公开(公告)号：US08349321B2

公开(公告)日：2013-01-08

申请号：US12572978

申请日：2009-10-02

Applicant: David J. Burke ,  Shaun E. Buckley ,  Sherwood Russ Lehrman ,  Barbara Horsey O'Connor ,  James Callaway ,  Christopher P. Phillips

Inventor： David J. Burke ,  Shaun E. Buckley ,  Sherwood Russ Lehrman ,  Barbara Horsey O'Connor ,  James Callaway ,  Christopher P. Phillips

IPC: A61K39/395

CPC classification number: C07K16/2839 ,  A61K39/39591 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/24

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract translation: 含有治疗有效量的抗体，聚山梨醇酯80，抑制聚山梨醇酯氧化的缓冲液的稳定的含水药物制剂与制备方法一起描述。 还描述了具有高抗体浓度的制剂，其保持固定体积并且可以用于可变重量的患者。

公开(公告)号：US08277808B2

公开(公告)日：2012-10-02

申请号：US11732400

申请日：2007-04-03

Applicant: Michael J. Briskin

Inventor： Michael J. Briskin

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/06 ,  G01N33/53

CPC classification number: C07K14/70503 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2839 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  Y10S530/866

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof that bind naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds α4β7, and wherein said isolated antibodies and antigen-binding fragments thereof inhibit binding of said naturally occurring human MAdCAM to human α4β7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.

Abstract translation: 本发明涉及结合天然存在的人MAdCAM的分离的抗体及其抗原结合片段，其中所述天然存在的人MAdCAM包含与SEQ ID NO：2或SEQ ID NO：4具有至少90％序列同一性的多肽，所述多肽与SEQ ID NO：2或SEQ ID NO：4具有至少90％的序列同一性， 天然存在的人MAdCAM结合α4和bgr7，并且其中所述分离的抗体及其抗原结合片段抑制所述天然存在的人MAdCAM与人α4和b结合，并且其中所述抗体抑制RPMI 8866细胞对表达所述人的细胞的粘附 MAdCAM。

公开(公告)号：US08124350B2

公开(公告)日：2012-02-28

申请号：US11887782

申请日：2006-04-04

Applicant: Meena Subramanyam ,  Lakshmi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin Mcdaid Barbour ,  Julie Elizabeth Taylor

Inventor： Meena Subramanyam ,  Lakshmi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin Mcdaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/53 ,  G01N33/541 ,  G01N33/577

CPC classification number: G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.

Abstract translation: 本发明涉及用治疗性蛋白质治疗的受试者鉴定临床显着免疫应答的方法和产品。 本发明的第一方面涉及用治疗量的VLA4结合抗体（例如那他珠单抗）治疗的患者中鉴定临床显着免疫应答的方法和组合物。 本发明的第二方面涉及用于确定针对治疗性蛋白质的抗体滴度的样品收集的时间顺序细节，例如。 在两个不同的时间点收集至少两个样本。 本发明的第三方面涉及临床阈值水平的选择，其对应于未经治疗的患者的抗体滴度增加了该对照抗体滴度的两倍的标准偏差。

公开(公告)号：US20120027754A1

公开(公告)日：2012-02-02

申请号：US13204382

申请日：2011-08-05

Applicant: Dean Sheppard ,  Xiaozhu Huang ,  Shelia M. Violette

Inventor： Dean Sheppard ,  Xiaozhu Huang ,  Shelia M. Violette

IPC: A61K39/395 ,  A61P11/00 ,  A61P11/06

CPC classification number: C07K16/2839 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0368 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present invention relates to methods of asthma treatment and prevention using αvβ6 antagonists, such as αvβ6-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of αvβ6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection is associated with protection from the usual allergen-induced increase in airway epithelial mast cells.

Abstract translation: 本发明涉及使用αv＆bgr6拮抗剂如αv和bgr-6结合抗体的哮喘治疗和预防方法。 特别地，本发明涉及在慢性过敏原挑战小鼠中观察到的αv和bgr6的表达减少与气道敏感性增加之间的相关性的发现。 这种保护与通常的过敏原诱导的气道上皮肥大细胞增加有关。

公开(公告)号：US20110294982A1

公开(公告)日：2011-12-01

申请号：US12991576

申请日：2009-05-11

Applicant: Peter Vanlandschoot ,  Michael John Scott Saunders ,  Johannes Joseph Wilhelmus De Haard ,  Christophe Blanchetot ,  Theo Verrips ,  Marc Antoine Gijsbert Gilles Vooijs ,  Adrianus Johannes Groot ,  Mohamed El Khattabi

Inventor： Peter Vanlandschoot ,  Michael John Scott Saunders ,  Johannes Joseph Wilhelmus De Haard ,  Christophe Blanchetot ,  Theo Verrips ,  Marc Antoine Gijsbert Gilles Vooijs ,  Adrianus Johannes Groot ,  Mohamed El Khattabi

IPC: C07K14/00

CPC classification number: C07K16/2839 ,  C07K16/2842 ,  C07K16/2845 ,  C07K2317/22 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76

Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) Integrins, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as □amino acid sequences of the invention□ com□pounds of the invention□, poly□peptides of the invention□, respectively).

Abstract translation: 本发明涉及针对（如本文所定义的）整联蛋白以及包含或基本上由一个或多个这样的氨基酸序列组成的化合物或构建体，特别是蛋白质和多肽的氨基酸序列（也称为 本发明的□氨基酸序列□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

公开(公告)号：US20110064729A1

公开(公告)日：2011-03-17

申请号：US12846350

申请日：2010-07-29

Applicant: Julie TAYLOR ,  Theodore A. Yednock

Inventor： Julie TAYLOR ,  Theodore A. Yednock

IPC: A61K39/395 ,  A61P1/00 ,  A61P29/00 ,  A61P1/04

CPC classification number: C07K16/2839 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2842 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/56966 ,  G01N2333/4737 ,  G01N2333/7055

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract translation: 公开了通过施用特异性结合α-4整联蛋白或包含α-4整联蛋白的二聚体的药剂来长期减轻患者病理性炎症的方法。 所提供的药剂必须具有结合亲合力，使得给药足以抑制病理性炎症，并且该药物被长期施用以提供长期抑制病理性炎症。

公开(公告)号：US20110021744A1

公开(公告)日：2011-01-27

申请号：US12901039

申请日：2010-10-08

Applicant: Yong DAI ,  Yong Wang ,  Shengjin Jin ,  Deborah H. Meshulam ,  Godfrey W. Amphlett

Inventor： Yong DAI ,  Yong Wang ,  Shengjin Jin ,  Deborah H. Meshulam ,  Godfrey W. Amphlett

IPC: C07K14/62 ,  C07K16/00 ,  C07K14/54 ,  C07K14/545 ,  C07K14/55 ,  C07K14/555 ,  C07K14/485 ,  C07K14/495 ,  C07K14/50 ,  C07K14/535 ,  C07K14/475 ,  C07K14/53 ,  C07K14/79 ,  C07D305/14 ,  C07D491/14

CPC classification number: A61K47/6803 ,  A61K47/6809 ,  A61K47/6867 ,  C07K16/2839 ,  C07K16/2884 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/40

Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.

Abstract translation: 本发明提供了一种制备与药物化学偶联的细胞结合剂的方法。 该方法包括将接头共价连接到细胞结合剂，纯化步骤，将药物与细胞结合剂缀合，随后的纯化步骤。

公开(公告)号：US20100183599A1

公开(公告)日：2010-07-22

申请号：US12620050

申请日：2009-11-17

Applicant: Gregory R. Mundy ,  Toshiyuki Yoneda

Inventor： Gregory R. Mundy ,  Toshiyuki Yoneda

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K14/70542 ,  A61K38/00 ,  C07K16/2836 ,  C07K16/2839 ,  C07K16/2842

Abstract: Antagonists of α4 integrin/α4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their α4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

Abstract translation: 描述了抑制这种粘附的生物学作用的α4整联蛋白/α4整联蛋白配体粘附的拮抗剂，并详细说明了其使用方法。 这样的拮抗剂可用于抑制与多发性骨髓瘤相关的骨破坏。 多发性骨髓瘤细胞归巢到骨髓及其骨吸收因子的α4整联蛋白依赖性释放，导致多发性骨髓瘤患者的骨破坏被抑制。